M V Skriver1, K Borch-Johnsen, T Lauritzen, A Sandbaek. 1. Department of General Practice, School of Public Health, Aarhus University, Bartholins Allé 2, 8000, Aarhus C, Denmark. mette.skriver@alm.au.dk
Abstract
AIMS/HYPOTHESIS: Stepwise screening for type 2 diabetes will not only identify people with the disease or some other form of dysglycaemia (impaired fasting glucose or impaired glucose tolerance), but also many individuals who are phenotypically at high risk of developing diabetes, but currently have normal glucose tolerance (NGT). We therefore sought to assess whether HbA(1c) adds prognostic information in relation to all-cause mortality in people who have NGT and a high risk of type 2 diabetes mellitus. METHODS: In a Danish population-based stepwise screening programme for type 2 diabetes mellitus in general practice, we identified 15,634 persons at high risk of type 2 diabetes, who had NGT and a recorded HbA(1c) measurement. As comparison groups, we included 1,401 people identified as having type 2 diabetes mellitus and 8,149 individuals characterised as being at low risk of diabetes. All individuals were followed from time of screening (April 2001 to December 2006) until death or 31 October 2009. Excess mortality was estimated using Cox proportional hazard models with all-cause mortality as the outcome measure. RESULTS: Compared with individuals with NGT and HbA(1c) below 6.0%, adjusted hazard ratios were: 1.21 (95% CI 0.95-1.56) for individuals with NGT and HbA(1c) between 6.0% and 6.5%; 2.48 (95% CI 1.23-4.99) for individuals with NGT and HbA(1c) 6.5% or above (in this group there were eight deaths among 68 individuals); 1.73 (95% CI 1.40-2.13) for individuals with type 2 diabetes mellitus. CONCLUSIONS/ INTERPRETATION: HbA(1c) level in people with NGT and at high risk of diabetes was clearly associated with increased all-cause mortality.
AIMS/HYPOTHESIS: Stepwise screening for type 2 diabetes will not only identify people with the disease or some other form of dysglycaemia (impaired fasting glucose or impaired glucose tolerance), but also many individuals who are phenotypically at high risk of developing diabetes, but currently have normal glucose tolerance (NGT). We therefore sought to assess whether HbA(1c) adds prognostic information in relation to all-cause mortality in people who have NGT and a high risk of type 2 diabetes mellitus. METHODS: In a Danish population-based stepwise screening programme for type 2 diabetes mellitus in general practice, we identified 15,634 persons at high risk of type 2 diabetes, who had NGT and a recorded HbA(1c) measurement. As comparison groups, we included 1,401 people identified as having type 2 diabetes mellitus and 8,149 individuals characterised as being at low risk of diabetes. All individuals were followed from time of screening (April 2001 to December 2006) until death or 31 October 2009. Excess mortality was estimated using Cox proportional hazard models with all-cause mortality as the outcome measure. RESULTS: Compared with individuals with NGT and HbA(1c) below 6.0%, adjusted hazard ratios were: 1.21 (95% CI 0.95-1.56) for individuals with NGT and HbA(1c) between 6.0% and 6.5%; 2.48 (95% CI 1.23-4.99) for individuals with NGT and HbA(1c) 6.5% or above (in this group there were eight deaths among 68 individuals); 1.73 (95% CI 1.40-2.13) for individuals with type 2 diabetes mellitus. CONCLUSIONS/ INTERPRETATION: HbA(1c) level in people with NGT and at high risk of diabetes was clearly associated with increased all-cause mortality.
Authors: N Waugh; G Scotland; P McNamee; M Gillett; A Brennan; E Goyder; R Williams; A John Journal: Health Technol Assess Date: 2007-05 Impact factor: 4.014
Authors: Thomas Bobbert; Knut Mai; Antje Fischer-Rosinsky; Andreas F H Pfeiffer; Joachim Spranger Journal: Diabetes Care Date: 2009-10-06 Impact factor: 19.112
Authors: Michael Mendler; Andreas Schlotterer; Youssef Ibrahim; Georgi Kukudov; Thomas Fleming; Angelika Bierhaus; Christin Riedinger; Vedat Schwenger; Stephan Herzig; Markus Hecker; Jens Tyedmers; Peter P Nawroth; Michael Morcos Journal: Diabetologia Date: 2014-10-17 Impact factor: 10.122
Authors: Dorte Vistisen; Daniel R Witte; Eric J Brunner; Mika Kivimäki; Adam Tabák; Marit E Jørgensen; Kristine Færch Journal: Diabetes Care Date: 2018-02-16 Impact factor: 19.112
Authors: Susann Blüher; Jana Markert; Sabine Herget; Thomas Yates; Melanie Davis; Gabriele Müller; Thomas Waldow; Peter E H Schwarz Journal: Curr Diab Rep Date: 2012-04 Impact factor: 4.810